Skip to main content
. 2021 Jun 9;13(12):2898. doi: 10.3390/cancers13122898

Figure 4.

Figure 4

Toxicity profiles of the antibody–drug conjugates currently approved or in late stages of development. Abbreviations: WBC, white blood count; T-DM1, trastuzumab emtansine; T-Dxd, trastuzumab deruxtecan; neutr, neutrophil [7,25,42,56].